An Access to Information request to Health Canada for the 100% composition of vaccines given to infants received the response, "I regret to inform you that the exact composition of these vaccines cannot be disclosed to you as the information is protected under ATIA (Access to Information Act) Section 20(1)(a)(b)(c). This is a mandatory exemption which protects confidential business information."
The Act, under Third Party Information, states, 20. (1) Subject to this section, the head of a government institution shall refuse to disclose any record requested under this Act that contains a) trade secrets of a third party; b) financial, commercial, scientific or technical information that is confidential information supplied to a government institution by a third party and is treated consistently in a confidential manner by the third party; c) information the disclosure of which could reasonably be expected to result in material financial loss or gain to, or could reasonably be expected to prejudice the competitive position of, a third party; or d) information the disclosure of which could reasonably be expected to interfere with contractual or other negotiations of a third party."
http://www.vran.org/vaccines/anaphylaxis/vaccine-ana.htm
VETERINARY SERVICES MEMORANDUM NO. 800.51
It is understood that in some cases, adjuvants are purchased from another firm and therefore some of the data listed may be the proprietary information of the supplier and may not be available to an applicant buying the materials from that source. In this case, it is acceptable for the applicant to arrange to have the adjuvant supplier submit adjuvant information to the CVB, in a manner that protects confidential business information.
http://www.aphis.usda.gov/animal_health/vet_biologics/publications/memo_800_51.pdf
VLP. Drug delivery vehicles, adjuvants, and excipients shall not be deemed to be "active ingredients", except in the case where such delivery vehicle, adjuvant, or excipient is recognized as an active ingredient in accordance with 21 C.F.R. 210.3(b)(7).
Intellectual Property and Patents
Our policy is to pursue patents and to otherwise endeavor to protect our technology, inventions and improvements that are commercially important to the development of our business. We also rely upon trade secrets that may be important to the development of our business.
Our success will depend in large part on our ability to:
• obtain and maintain patent and other proprietary protection for the technology, inventions and improvements we consider important to our business;
• defend our patents;
• preserve the confidentiality of our trade secrets; and
...We also rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable.
http://www.123jump.com/10K_Reports/ANDS/2005/2005.htm
Exhibit D, Trade Secret/Confidential Information--(enclosed separately)
http://www.patentstorm.us/patents/6398774/description.html
The nature of GlaxoSmithKline's adjuvant is a trade secret, but David Stout, president for worldwide pharmaceuticals at the company, said the ingredients had already been given to people in other products, though not in this particular combination.
http://query.nytimes.com/gst/fullpage.html?sec=health&res=9a00e2d8153ff934a15754c0a9609c8b63
"Today, the whole-cell vaccine is made in essentially the same way as in the time of Bordet and Gengou, although each manufacturer prepares it differently, and the exact formula is considered a trade secret."
from A Shot in the Dark By Harris L. Coulter, Barbara Loe Fisher
Qualifying for Trade Secret Protection
The case of Merck & Co., Inc. v. Smithkline Beecham Pharmaceuticals gives an example. The plaintiff claimed trade secret protection for a process it developed for the production of a vaccine. The defendant claimed that the process was not a trade secret because its aspects were readily ascertainable in publications. The court rejected the defendant’s argument, stating that “[T]he choice of individually known components and techniques to create a working manufacturing process is often, as here, a difficult undertaking. Where at individual steps of a process there are a variety of alternatives, the choice made through much effort of specific ingredients, materials, conditions and steps in an actual, working process constitutes a trade secret.”
http://www.henkebartram.com/articles/Qualifying-for-Trade-Secret-Protection.pdf
If we are unable to protect our proprietary technology, we may not be able to compete as effectively.
The pharmaceutical industry places considerable importance on obtaining patent and trade secret protection for new technologies, products and processes. Our success will depend, in part, upon our ability to obtain, enjoy and enforce protection for any products we develop or acquire under United States and foreign patent laws and other intellectual property laws, preserve the confidentiality of our trade secrets and operate without infringing the proprietary rights of third parties.
http://forbes.brand.edgar-online.com/fetchFilingFrameset.aspx?dcn=0001362310-08-001488&Type=HTML
The process to create their fermented yeast product is not patented, but it is a trade secret that no competitor has yet to copy. An analysis of the product by investigators came up with even more startling details.
Squaline was found. Squaline comes mainly from shark liver but is also found in a handful of plants.
http://us.mc8.mail.yahoo.com/mc/compose?.rand=325538557&uc=1
Because the actual levels of thimerosal used in each vaccine are a trade secret, we were not able to directly control for possible exposure to thimerosal in our analysis.
http://www.ehponline.org/docs/2008/116-10/EHP116pa418PDF.PDF
Universal Vaccine Purchase and Provision
The bill would require that the Secretary consult with other Federal agencies for advice on the quantities of recommended childhood vaccine to be purchased. It would authorize the Secretary to consult with representatives of State governments, experts in vaccine delivery, health care providers, and other experts prior to commencing negotiations for the purchase of vaccine.
This proposal would direct the Secretary to negotiate a reasonable price with manufacturers participating in a procurement. The price would be based on data supplied to the Secretary by manufacturers regarding (1) costs related to research and development, production, distribution to States and health care providers, and marketing; (2) profit levels sufficient to encourage future investment in research and development; and (3) the ability to maintain adequate outbreak control. In addition, the bill would require that data provided to the Secretary be treated as a trade secret or confidential information for purposes of the Freedom of Information Act and would provide criminal sanctions for violations of this provision.
http://www.ibiblio.org/pub/archives/whitehouse-papers/1993/Apr/Immunization-Fact-Sheet-4193
A bill to be entitled
2 An act relating to public records exemptions;
3 creating s. 288.961, F.S.; clarifying the
4 public records exemption relating to trade
5 secrets for proprietary confidential business
6 information owned or controlled by the
7 not-for-profit corporation operating the
8 Florida Vaccine Research Institute and its
9 subsidiaries; expanding the public records
10 exemption to include information received from
11 a person in this or another state or nation or
12 the Federal Government which is otherwise
13 exempt or confidential under the laws of this
14 or another state or nation or under federal
15 law; providing for future review and repeal;
16 providing a statement of public necessity;
17 providing an effective date.
http://www.leg.state.fl.us/data/session/2005/Senate/bills/billtext/pdf/s2034.pdf
8. Was Traci Johnson driven to suicide by anti-depressants? That's a trade secret, ... Was Traci Johnson driven to suicide by anti-depressants? That's a trade secret, say US officials Search Archives Preview New Site About AHRP / Mission Statement What's...
URL: http://www.ahrp.org/infomail/05/06/19.php Score: 18% Date: - Size: 19 kB
Intellectual Property Protection for Plant Derived Vaccine Technology:
Here They Come Are we Ready or Not?
Presently the most common source of IP protection sought for PDVs is a patent. PDVs may also be protected as trade secrets. Trade secret protection is not grounded in statute, but is rooted in business practices which protect confidentiality of information relating to an innovation.8 Trade secret protection relies upon confidentiality rather than registration and is understood to be an alternative to patent protection.9 Reliance upon confidentiality renders trade secret a fragile IP right, because the protection can be immediately and irretrievably lost upon disclosure. Nowadays, due to innovations which promote quick and wide-spread distribution of information, such as the internet, trade secret protection can literally be lost at the push of a button. The upside of trade secret protection is the competitive advantage that it can provide because, unlike patents, no public disclosure is required. In an environment where adequate confidentiality measures are in place and enforceable, trade secrets provide an effective means of concealing information from the public and thereby securing a market sector monopoly.10
http://www.lex-electronica.org/docs/articles_71.pdf
(1) that is trade secret or commercial or financial in substance and is privileged or confidential; or
http://www.uscfc.uscourts.gov/book/export/html/4044
Introduction to U.S. Intellectual Property Law
by Robert L. Vienneau, ITT Corporation and Milton Johns, ITT Corporation
Trade secrets are defined in a slightly different way in each state, but the Uniform Trade Secrets Act, as amended in 1980 (hereafter “UTSA”), is a good point of departure for a general definition. Under the UTSA,
“ ‘Trade secret’ means information, including a formula, pattern, compilation, program, device, method, technique, or process, that (i) derives independent economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use, and (ii) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy.”
https://www.softwaretechnews.com/stn_view.php?stn_id=45&article_id=109 - broken link
People should also know that the manufacturers do not disclose all the ingredients nor full details of the manufacturing process. Health Canada protects the "proprietary rights" of these companies and upholds their right to secrecy - something the greater Canadian public should be up in arms about. That parents are expected to submit their children for injection with multiple vaccines without first having full disclosure of all known ingredients is a disturbing statement on the control exerted by monopoly medicine and corporate and government allies.
http://www.vran.org/vaccines/vacing/vac-ing-can.htm - broken link
Strangely vaccine damaged children also have high levels of arsenic and lead in their bodies. Are these also a component of vaccines? Unless a full disclosure is made it is difficult to say what exactly vaccines are composed of.
http://www.udaan.org/autism/vaccine_safety.html
Labeling of GMO-Derived Food Ingredients: A Recipe for Misinformation
The consumer’s need for accurate information is of paramount importance: no one here disputes this fact. What we all should remember, however, is that this need is not a mandate for selective inclusion of label information by individuals or groups that may support or oppose a given technology or ingredient. There is, rather, an ethical and moral imperative to provide full, accurate and non-misleading information that is of real value to consumers. The consumer has no right to misleading information and does not wish to be misled. A simple statement regarding the presence of genetically modified components, delivered out of context and without appropriate elaboration, fails this test entirely. Inaccurate and misleading information is worse than no information at all. For this reason this Committee should, indeed must, oppose any further efforts to mandate, endorse or agree to uninformative, inaccurate and incomplete labeling cloaked in the guise of full disclosure, until such time as it can establish meaningful criteria to ensure that consumers receive the whole story, and not just what one or another interested party would like them to know.
http://www.khlaw.com/showpublication.aspx?Show=608
A northern state in Nigeria that is at the heart of a spreading polio outbreak said Sunday that it would not relent on its boycott of a mass vaccination program, which it has called a U.S. plot to spread AIDS and infertility among Muslims ....Kano state officials say their lab tests carried out late last year found estrogen and other female sex hormones in the polio vaccine -- proof, they say, that the vaccines are contaminated.
[Media Feb 2004] Province at heart of outbreak alleges anti-Muslim plot
The Associated Press obtained a copy of the committee's interim report that ruled the vaccines safe. However, it acknowledged the tests showed "trace amounts of estradiol," a form of the female hormone estrogen the vaccine's Muslim detractors claim could cause infertility. ...Muslims in Nigeria's north have been wary of vaccine campaigns since 1996, when families in Kano state accused New York-based Pfizer Inc. of using an experimental meningitis drug without fully informing of the risks.....The company denied any wrongdoing. A U.S. court dismissed a lawsuit by 20 disabled Nigerians who allegedly took part in the study, but a U.S. appeals court later revived it.
Vaccine Boycott Grows in Northern Nigeria
At the June 15 hearing, officials from the FDA and CDC defended the various conflicts of interest because waivers were granted. One CDC official went so far as to suggest that it good to use vaccine industry insiders on official advisory committees because they are able to vote based on secret drug-company information!
It is a great mistake to make vaccine policy based on confidential or trade secret data. Science is most reliable when all data and analyses are subject to public scrutiny, and our political system demands that government policy decisions be subject to democratic checks and balances.
http://home.rica.net/ideagle/ImmunizationCode.html
MEMORANDUM OF UNDERSTANDING BETWEEN THE FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES OF THE UNITED STATES OF AMERICA
AND THE HEALTH PRODUCTS AND FOOD BRANCH HEALTH CANADA OF CANADA
REGARDING SHARING AND EXCHANGE OF INFORMATION ABOUT THERAPEUTIC PRODUCTS
CONFIDENTIALITY
Information exchanged under this MOU may include non-public information exempt from public disclosure under the laws and regulations of the United States and Canada. Information that is not appropriate for public dissemination is only to be shared according to the procedures and policies of the Participants as permitted by these respective laws. Neither the USFDA nor Canada HPFB may divulge trade secret information without the consent of the owner. With regard to any non-public information that may be provided to Canada HPFB by USFDA or to the USFDA by Canada HPFB, such transmissions are to be made in accordance with the specific signed confidentiality commitments and other requirements of the Participants.